Immunogenicity Data News Today

-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed...

The Food and Drug Administration is charged with making sure products, including medicines, delivered to American consumers have been tested for safety.

-- Infant Phase 2 Study Initiation Expected in the Second Quarter of 2023, with Initial Topline Safety, Tolerability and Immunogenicity Data by 2025 -- -- Based on Positive Topline VAX-24 Phase 1/2... | February 21, 2023

Announced Publication of ADXS-PSA Data in The Oncologist Presented Updated Clinical and Immunogenicity Data from Ongoing Phase 1/2 Trial of ADXS-503 in...

Overall response rate of 14% and disease control rate of 36% in Part B of ADXS-503 trial with durable clinical benefit as an add-on therapy to patients...

Months after the primary series and all we have are what are called serologic data, antibody data, measured four weeks and six weeks after the booster. we dont have effectiveness. these are just the immunogenicity data. i can imagine the fda will have their hands full in the next day and a half to really get their brains around all of this. im still in the middle of getting through it all. its pretty complicated. >> i bet, it is. and listen, this just came out this afternoon. it is developing as...

Jake? >> yeah, theyve been criticized, in fact, the biden administration for putting pressure on the fda. elizabeth cohen, thank you so much. i want to bring in a professor at vanderbilt medical center who studies infectious disease and preventive medicine. dr. schaffner, what do you make of this first vote by the fda panel against recommending a third dose or a booster for all americans 16 and over? >> actually, jake, im rather surprised because i would have thought that the committee would loo...

To get under the veil of protection of a vaccine. right now, we, at the nih, the companies are all doing studies to do what we call age deescalation. looking at 11 to 9, 9 to 6, 6 to 2. and then, six months to two years, were collecting safety data and were collecting immunogenicity data. were going to have enough data where the companies will be able to present the data to the cdc by the mid-fall or so. somewhere around september or octob october for pfizer. a little bit later for moderna. the ...

Appropriately is what about 11 down to 5 and even lower, namely the elementary school kids who everyone really wants to get under the veil of protection of a vaccine. right now we at the nih, the companies are all doing studies to do what we all age de-escalation, looking at 11 to 9, 9 to 6, 6 to 2, and then 6 months to 2 years. were collecting safety data and were collecting immunogenicity data. well have enough data to present to the cdc by mid-fall or so, september, october, for pfizer. a lit...

Representative image ANI | Updated: Feb 24, 2021 22:15 IST New Delhi [India], February 24 (ANI): The Central Drugs Standard Control Organisations (CDSCO) Subject Expert Committee (SEC) has recommended additional immunogenicity data from Dr Reddys Laboratories which applied to the national drugs regulator seeking emergency use approval for Sputnik V, a Russian COVID-19 Vaccine. "Today, SEC meeting helped discuss the application of Dr Reddy seeking emergenc...